The Effect of Bevacizumab on Corneal Neovascularization

Summary

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Timeline

Start

2006-01

Primary completion

2008-07

Completion

2008-11

Drugs

Indications